When should hemodialysis or plasma exchange be used to reduce early death in hemophagocytic lymphohistiocytosis?

International Medical Journal

Volumn 19, Issue 1, 2012, Pages 27-30

  He, Aili ^a   Zhang, Wanggang ^a   Niu, Yu ^b   Wang, Jianli ^a   Chao, Xingmei ^a   Yang, Yun ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^b SHAANXI PROVINCIAL PEOPLE S HOSPITAL   (China)

Author keywords

Early death; Hemophagocytic lymphohistiocytosis (HLH); Plasma exchange; Serum ferritin

Indexed keywords

CYCLOSPORIN A; DEXAMETHASONE; ETOPOSIDE; FERRITIN; LACTATE DEHYDROGENASE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; CLINICAL ARTICLE; DEATH; EPSTEIN BARR VIRUS INFECTION; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HEMODIALYSIS; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HOSPITAL ADMISSION; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPHOMA; MALE; PLASMAPHERESIS; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

EID: 84859920093     PISSN: 13412051     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Henter JI, Elinder G. Familial hemophagocytic lymphohistiocytosis. Clinical review based on the findings in seven children. Acta Paediatr Scand 1991; 80: 269-277.
2. Janka G, Elinder G, Imashuku S, et al. Infection- and malignancy-associated hemo-phagocytic syndromes: Secondary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am 1998; 12: 435-444. (Pubitemid 28175891)
3. Jan-Inge Henter, Anna Carin Horne. HLH-2004: Diagnostic and Therapeutic Guidelines for Hemophagocytic Lymphohistiocytosis. Pediatr Blood Cancer, 2007; 48: 124-131. (Pubitemid 44958267)
4. Shinsaku Imashuku. Advances in the Management of Hemophagocytic Lymphohistiocytosis. Int J Hematol 2000; 72: 1-11
5. Shinsaku Imashuku, Tomoko Teramura. Longitudinal follow-up of patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Haematologica 2004; 89: 183-188. (Pubitemid 38796492)
6. Yoshihisa Tateishi, Shigeto Oda, Tomohito Sadahiro, et al. Continuous hemodiafiltra-tion in the treatment of reactive hemophagocytic syndrome refractory to medical therapy. Transfus Apheresis Sci 2009: 40: 33-40.
7. Kizaki Z, Fukumochi H, Sawai T, et al. Exchange transfusion and combination chemotherapy in the treatment of 4 cases of childhood malignant histiocytosis. Rinsho Ketsueki 1987; 28: 845-851.
8. Matsumoto Y, Naniwa D, Banno S, et al. The efficacy of therapeutic plasmapheresis for the treatment of fatal hemophagocytic syndrome: two case reports. Ther Apher 1998; 2: 300-304. (Pubitemid 28544149)
9. Ho-Jin Shin, Joo Seop Chung, Je-Jung Lee, et al. Treatment Outcomes with CHOP Chemotherapy in Adult Patients with Hemophagocytic Lymphohistiocytosis. J Korean Med Sci 2008; 23: 439-444.
10. Henter JI, Samuelsson-Horne A, Arico M, et al. Treatment of hemophagocytic lym-phohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood 2002; 100: 2367-2373.
11. Kaito K, Kobayashi M, Katayama T, et al. Prognostic factors of hemophagocytic syndrome in adults: analysis of 34 cases. Eur J Haematol 1997; 59: 247-53. (Pubitemid 27425467)
12. Imashuku S, Hibi S, Sako M, et al. Soluble interleukin-2 receptor: a useful prognostic factor for patients with hemophagocytic lymphohistiocytosis [letter]. Blood 1995; 86: 4706-4707.
13. Fukaya S, Yasuda S, Hashimoto T, et al. Clinical features of haemophagocytic syndrome in patients with systemic autoimmune disease: analysis of 30 cases [J]. Rheumatology 2008, 47: 1686-1691.
14. Ishii E, Ohga S, Aoki T, et al. Prognosis of children with virus-associated hemophago-cytic syndrome and malignant histiocytosis: correlation with levels of serum inter-leukin-1 and tumor necrosis factor. Acta Haematol 1991; 85: 93-99.
15. Esumi N. Hyperferritinemia in malignant histiocytosis and virus associated hemo-phagocytic syndrome. N Engl J Med 1987; 316: 346-347. (Pubitemid 17036391)
16. Moss DW, Henderson AR. Clinical enzymology. In Ca Burtis and Er Ashwood (Eds), Tietz textbook of clinical chemistry 3rd ed. (pp. 617-721). Philadelphia: Saunders, 1999.
17. Adiga SK, Jagetia GC. Effect of teniposide (VM-26) on cell survival, micronuclei-induction and lactate dehydrogenase activity on V79 cells. Toxicology 1999; 29: 29-41. (Pubitemid 29476569)
18. Fariss MW, Brown MK, Schmitz JA, et al. Mechanism of chemical-induced toxicity. Part I. Use of a rapid centrifugation technique for the separation of viable and nonvi-able hepatocytes. Toxicol Appl Pharmacol 1985; 30: 283-295. (Pubitemid 15013733)
19. Miller BG, Armstrong DT. Superovulatory doses of pregnant mare serum gonadotropin cause delayed implantation and infertility in immature rats. Biol Reprod 1981; 25: 253-260. (Pubitemid 11029383)
20. International Germ Cell Cancer Collaborative Group. International germ cell concensus classification. A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15: 594-603.
21. International Union Against Cancer, Sobin LH, Wittekind C. TNM classification of malignant tumours. 5th ed. New York: Wiley-Liss, 1997.
22. Imashuku S, Hibi S, Ohara T, et al. Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Blood 1999; 93: 1869-1874. (Pubitemid 29128488)
23. Imashuku S, Hibi S, Kuriyama K, et al. Management of severe neutropenia with cyclosporin during initial treatment of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis. Leuk Lymphoma 2000; 36: 339-346. (Pubitemid 30060185)
24. Imashuku S, Kuriyama K, Teramura T, et al. Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Clin Oncol 2001; 19: 2665-2673. (Pubitemid 32441371)
25. Imashuku S. Clinical features and treatment strategies of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Crit Rev Oncol Hematol 2002; 44: 259-272. (Pubitemid 35435291)
26. Miyahara M, Sano M, Shibata K, et al. B-cell lymphoma-associated hemophagocytic syndrome: clinicopathological characteristics. Ann Hematol 2000; 79: 378-388. (Pubitemid 30459663)